Back to Browse Journals » Biologics: Targets and Therapy » Volume 3

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia

Authors Eric Cheung, Howard A Liebman

Published Date January 2009 Volume 2009:3 Pages 57—62

DOI http://dx.doi.org/10.2147/BTT.S3166

Published 8 January 2009

Eric Cheung, Howard A Liebman

Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California-Keck School of Medicine, Los Angeles, CA, USA

Abstract: Immune thrombocytopenia (ITP) is an acquired bleeding autoimmune disorder characterized by a markedly decreased blood platelet count. The disorder is variable, frequently having an acute onset of limited duration in children and a more chronic course in adults. A number of therapeutic agents have demonstrated efficacy in increasing the platelet counts in both children and adults. Anti-RhD immunoglobulin (anti-D) is one such agent, and has been successfully used in the setting of both acute and chronic immune thrombocytopenia. In this report we review the use of anti-D in the management of ITP. While the FDA-approved dose of 50 mg/kg has documented efficacy in increasing platelet counts in approximately 80% of children and 70% of adults, a higher dose of 75 μg/kg has been shown to result in a more rapid increase in platelet count without a greater reduction in hemoglobin. Anti-D is generally ineffective in patients who have failed splenectomy. Anti-RhD therapy has been shown capable of delaying splenectomy in adult patients, but does not significantly increase the total number of patients in whom the procedure can be avoided. Anti-D therapy appears to inhibit macrophage phagocytosis by a combination of both FcR blockade and inflammatory cytokine inhibition of platelet phagocytosis within the spleen. Anti-RhD treatment is associated with mild to moderate infusion toxicities. Rare life-threatening toxicities such as hemoglobinuria, acute renal failure and disseminated intravascular coagulation have been reported. Recommendations have been proposed to reduce the risk of these complications. Anti-D immunoglobulin can be an effective option for rapidly increasing platelet counts in patients with symptomatic ITP.

Keywords: immune thrombocytopenia, RhD immunoglobulin

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins

Benucci M, Li Gobbi F , Meacci F, Manfredi M, Infantino M, Severino M, Testi S, Sarzi-Puttini P, Ricci C, Atzeni F

Biologics: Targets and Therapy 2015, 9:7-12

Published Date: 17 February 2015

Drug therapies and presence of coronary artery disease may affect aortic stiffness in Alzheimer’s disease

Bektaş O, Günaydın ZY, Karagöz A, Kaya A

Clinical Interventions in Aging 2015, 10:469-471

Published Date: 13 February 2015

Value of portal venous system radiological indices in predicting esophageal varices

Gaduputi V, Patel H, Sakam S, Neshangi S, Ahmed R, Lombino M, Chilimuri S

Clinical and Experimental Gastroenterology 2015, 8:89-93

Published Date: 9 February 2015

Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines

Lam DC, Luo SY, Deng W, Kwan JS, Rodriguez-Canales J, Cheung AL, Cheng GH, Lin CH, Wistuba II, Sham PC, Wan TS, Tsao SW

OncoTargets and Therapy 2015, 8:195-209

Published Date: 16 January 2015

Adiponectin as a potential biomarker of vascular disease

Ebrahimi-Mamaeghani M, Mohammadi S, Arefhosseini SR, Fallah P, Bazi Z

Vascular Health and Risk Management 2015, 11:55-70

Published Date: 16 January 2015

Chloronychia: green nail syndrome caused by Pseudomonas aeruginosa in elderly persons

Chiriac A, Brzezinski P, Foia L, Marincu I

Clinical Interventions in Aging 2015, 10:265-267

Published Date: 14 January 2015

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010

Wound care in the geriatric client

Steve Gist, Iris Tio-Matos, Sharon Falzgraf, Shirley Cameron, Michael Beebe

Clinical Interventions in Aging 2009, 4:269-287

Published Date: 8 June 2009